Dr Schwartz gives an expert commentary on data presented at ASCO 2015.
452 patients with advanced leiomyosarcoma or adipocytic sarcoma, which is also called liposarcoma, were randomly assigned to treatment with eribulin or dacarbazine until disease progression.
The median overall survival was 13.5 months in the eribulin group and 11.5 months in the dacarbazine group.
Dr Schwartz looks at the implications of this and gives some background on the difficulty of treating sarcomas.
Read the news story for more.